Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries
Options
BORIS DOI
Date of Publication
2007
Publication Type
Article
Division/Institute
Author
Brinkhof, MW | |
Egger, M | |
Boulle, A | |
May, M | |
Hosseinipour, M | |
Sprinz, E | |
Braitstein, P | |
Dabis, F | |
Reiss, P | |
Bangsberg, DR | |
Rickenbach, M | |
Miro, JM | |
Myer, L | |
Mocroft, A | |
Nash, D | |
Keiser, O | |
Pascoe, M | |
van der Borght, S | |
Schechter, M |
Series
Clinical infectious diseases
ISSN or ISBN (if monograph)
1058-4838
Publisher
Oxford University Press
Language
English
Publisher DOI
PubMed ID
17990236
Description
We examined the incidence of and risk factors for tuberculosis during the first year of highly active antiretroviral therapy in low-income (4540 patients) and high-income (22,217 patients) countries. Although incidence was much higher in low-income countries, the reduction in the incidence of tuberculosis associated with highly active antiretroviral therapy was similar: the rate ratio for months 7-12 versus months 1-3 was 0.48 (95% confidence interval, 0.36-0.64) in low-income countries and 0.36 (95% confidence interval, 0.26-0.50) in high-income countries. A low CD4 cell count at the start of therapy was the most important risk factor in both settings.
File(s)
File | File Type | Format | Size | License | Publisher/Copright statement | Content | |
---|---|---|---|---|---|---|---|
45-11-1518.pdf | text | Adobe PDF | 126.79 KB | publisher | published |